Is CJC-1295/ipamorelin worth it?
Studies of the individual ingredients do not establish how well a CJC-1295/ipamorelin blend improves sleep, body composition or recovery. The exact formulation matters as much as the names on the label.
What the CJC-1295 study measured
Short randomized studies of long-acting CJC-1295 measured growth hormone and IGF-1 responses in healthy adults. They were not trials of this two-drug blend. Their duration and long-acting formulation also matter; results cannot simply be transferred to a preparation described as no-DAC.
Read: Teichman et al. Long-acting CJC-1295 in healthy adults.
What the ipamorelin study measured
A randomized IV ipamorelin study after bowel surgery did not find significant differences on its primary or secondary efficacy outcomes. That trial neither proves nor tests the usual wellness claims made for a subcutaneous blend.
Make the proposal specific
Ask for the exact ingredients and formulation, the treatment goal, the evidence for that goal and the monitoring plan. An increase in a hormone marker is not automatically a reason to pay for ongoing treatment. Review the safety questions before deciding.
Sources
- Teichman et al. Long-acting CJC-1295 in healthy adults
JCEM, 2006. Short studies of GH and IGF-1 responses; not a trial of the CJC-1295/ipamorelin blend.
- Beck et al. IV ipamorelin after bowel surgery
International Journal of Colorectal Disease, 2014. Different route, population and outcome from wellness use.
- FDA: Compounding questions and answers
The distinction between compounded medications and FDA-approved drug products.
